Why This Biotech Fund Increased Its Oruka Stake Amid a 500% Rally
A biotech fund just boosted its Oruka Therapeutics position after a blistering rally. Here’s what the move signals ab...
Why Active Funds May Underperform Benchmarks discusses persistent headwinds, costs, and timing issues that hinder outperformance.
26,804 articlesA biotech fund just boosted its Oruka Therapeutics position after a blistering rally. Here’s what the move signals ab...
CrossCountry Mortgage plans a pro rata quarterly dividend for Two Harbors shareholders in the deal closing quarter, a...
As lawmakers push hundreds of AI bills, a lack of universal testing leaves companies and investors facing a maze of r...
A top healthcare fund just lined up another $11 million in a biotech that’s surged 60%. We break down why the move ma...
Looking for a long-term growth plan? This article highlights three growth stocks to hold next for the next two decade...
New to real estate investing? This ultimate guide buying off-market walks you through where to find deals, how to fin...
Moving abroad can shake up your retirement plans. This guide explains how Social Security works when you live abroad,...
Viasat stock went moon as part of a broader space-sector rally. This article dives into the drivers, what it means fo...
A troubling local case shows how a fake voter guide can blend into the political scene and affect your finances. Lear...
Investors chasing high-tech breakthroughs often bet on early-stage companies like Rigetti. This article breaks down w...
On a day when the markets attempted a comeback, FuboTV stunned traders with a sharp drop. This article breaks down wh...
Money dynamics in relationships vary as widely as people do. This guide uses playful animal personalities to show whi...